Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis-Reference-Cited by-同舟云学术

Real-World Experience with Nintedanib in Patients with Idiopathic Pulmonary Fibrosis

Published:2018 Issue:5 Volume:95 Page:301-309
ISSN:0025-7931
Container-title:Respiration
language:en
Short-container-title:Respiration

Author:

Brunnemer Eva,Wälscher Julia,Tenenbaum Svenja,Hausmanns Julia,Schulze Karen,Seiter Marianne,Heussel Claus Peter,Warth Arne,Herth Felix J.F.,Kreuter Michael

Publisher

S. Karger AG

Subject

Pulmonary and Respiratory Medicine

Reference27 articles.

1. Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, Wirtz H, Koschel D, Andreas S, Claussen M, Grohe C, Wilkens H, Hagmeyer L, Skowasch D, Meyer JF, Kirschner J, Glaser S, Herth FJF, Welte T, Neurohr C, Schwaiblmair M, Held M, Bahmer T, Frankenberger M, Behr J: Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: INSIGHTS-IPF registry. Respir Res 2017; 18: 139.

2. Kreuter M, Ehlers-Tenenbaum S, Palmowski K, Bruhwyler J, Oltmanns U, Muley T, Heussel CP, Warth A, Kolb M, Herth FJ: Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis. PLoS One 2016; 11:e0151425.

3. Kreuter M, Bonella F, Maher TM, Costabel U, Spagnolo P, Weycker D, Kirchgaessler KU, Kolb M: Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis. Thorax 2017; 72: 148–153.

4. Kreuter M, Wijsenbeek MS, Vasakova M, Spagnolo P, Kolb M, Costabel U, Weycker D, Kirchgaessler KU, Maher TM: Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis. Eur Respir J 2016; 47: 1776–1784.

5. Kreuter M, Wuyts W, Renzoni E, Koschel D, Maher TM, Kolb M, Weycker D, Spagnolo P, Kirchgaessler KU, Herth FJ, Costabel U: Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respir Med 2016; 4: 381–389.

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The dorsal muscle group area at the T12 vertebral level as a risk factor for tolerability of nintedanib in patients with idiopathic pulmonary fibrosis or other progressive fibrosing interstitial lung diseases;Medicine;2024-07-12

2. Real-world safety and effectiveness of pirfenidone and nintedanib in the treatment of idiopathic pulmonary fibrosis: a systematic review and meta-analysis;European Journal of Clinical Pharmacology;2024-07-04

3. Pirfenidone and Nintedanib in Pulmonary Fibrosis: Lights and Shadows;Pharmaceuticals;2024-05-30

4. The tolerability and efficacy of antifibrotic therapy in patients with idiopathic pulmonary fibrosis: Results from a real-world study;Pulmonary Pharmacology & Therapeutics;2024-03

5. Prostaglandin E2 (PGE2) and Roflumilast Involvement in IPF Progression;International Journal of Molecular Sciences;2023-08-03